Research & Development
Sysmex Corporation presented the latest data on Alzheimer's Disease diagnostics using blood at "The 15th Clinical Trials on Alzheimer's Disease (CTAD) " to be held from November 29 to December 2, 2022 in San Francisco, California, United States.
Session | Subject | Presenter (Affiliation) |
Poster: Clinical Trials: Biomarkers including plasma (LP84A*1) |
Three group classification of participants based on fully automated plasma β-amyloid measurements to achieve high positive and negative predictive values. Poster presentation:December 1 (Thursday) 8:00 - 18:00 (PST) https://www.sysmex.co.jp/en/rd/report/221212a.html |
Kazuto Yamashita (SYSMEX) |
Poster: Clinical Trials: Biomarkers including plasma (LP74) |
Effects of pre-analytical parameters on plasma β-amyloid level. Poster presentation:December 1 (Thursday) 8:00 - 18:00 (PST) https://www.sysmex.co.jp/en/rd/report/221212b.html |
Kengo Ishiki (SYSMEX) |
Poster: Clinical Trials: Biomarkers including plasma (LP68*2) |
Age dependency of plasma β-amyloid measured by fully automated and highly specific immunoassays in a Japanese cohort study (SESSA). Poster presentation:December 1 (Thursday) 8:00 - 18:00(PST) https://www.sysmex.co.jp/en/rd/report/221212c.html |
Kengo Ishiki (SYSMEX) |
Terminology | ||
1 | Joint announcement with Sysmex Corporation, Eisai Co., Ltd., and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology. | |
2 | Joint announcement with Sysmex Corporation, and Shiga University of Medical Science. |